|
| Press Releases |
|
 |
|
| Wednesday, September 17, 2025 |
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
| Friday, September 12, 2025 |
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the release of a concept movie and new content on the dedicated website for its "New Answers to Dementia" campaign, designed to increase corporate awareness. more info >> |
|
| Monday, September 8, 2025 |
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
| Thursday, September 4, 2025 |
|
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
| Wednesday, September 3, 2025 |
|
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, September 1, 2025 |
|
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
| Friday, August 29, 2025 |
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Monday, August 25, 2025 |
|
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. more info >> |
|
|
エーザイとバイオジェン、アルツハイマー病治療剤「レケンビ」（レカネマブ）をドイツ、オーストリアにおいて新発売 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、抗 Aβモノクローナル抗体「レケンビ」（一般名：レカネマブ）について、オーストリアで 8 月 25 日に、ドイツでは 9 月 1 日にそれぞれ新発売することをお知らせします。 more info >> |
|
| Monday, August 18, 2025 |
|
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
隨著歐洲與東南亞吸納越來越多國際護理人員，全球護理人員遷徙模式正發生轉變
Apr 28, 2026 22:00 HKT/SGT
|
|
|
随着欧洲和东南亚吸纳的国际护士比例不断上升，全球护士流动格局正在发生变化
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Tenstorrent、新たなネットワーク型AIアーキテクチャ上で展開される業界最高水準の性能により大規模AIを実現
Apr 28, 2026 22:00: JST
|
|
|
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture
Apr 28, 2026 21:00 HKT/SGT
|
|
|
TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST
|
|
|
HKTDC's response to Hong Kong's export figures for March
Apr 28, 2026 19:23 HKT/SGT
|
|
|
CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion
Apr 28, 2026 19:11 HKT/SGT
|
|
|
康希諾生物一季度業績穩健增長 全生命週期佈局打開長期價值空間
Apr 28, 2026 19:04 HKT/SGT
|
|
|
Kincora Commences Drilling at the Historic Condobolin Mining Field
Apr 28, 2026 19:00 HKT/SGT
|
|
|
由美國馬球協會（U.S. Polo Assn.）與 ESPN 共同贊助的「美國公開馬球錦標賽(R)」決賽圓滿落幕，為本季創下多項紀錄的美國馬球賽季畫下句點
Apr 28, 2026 19:00 HKT/SGT
|
|
|
由美国马球协会（U.S. Polo Assn.）和ESPN联合呈现的著名美国公开马球锦标赛（U.S. Open Polo Championship(R)）决赛，为这个创下多项纪录的美国马球赛季画上了句号
Apr 28, 2026 19:00 HKT/SGT
|
|
|
The Prestigious U.S. Open Polo Championship(R) Final Closes a Record-Breaking American Polo Season, Supported by U.S. Polo Assn. and ESPN
Apr 28, 2026 19:00 HKT/SGT
|
|
|
康希诺生物一季度业绩稳健增长 全生命周期布局打开长期价值空间
Apr 28, 2026 18:58 HKT/SGT
|
|
|
NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
Apr 28, 2026 19:05 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
